Andreas M Hötker1,2, Andreas Meier3,4, Yousef Mazaheri5, Junting Zheng6, Marinela Capanu6, Joshua Chaim3, Ramon Sosa3, Jonathan Coleman7, Hedvig Hricak3, Oguz Akin3. 1. Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA. Andreas.Hoetker@usz.ch. 2. Department of Diagnostic and Interventional Radiology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland. Andreas.Hoetker@usz.ch. 3. Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA. 4. Department of Diagnostic and Interventional Radiology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland. 5. Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 6. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 7. Department of Surgery, Urology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Abstract
PURPOSE: The purpose of our study was to retrospectively evaluate and categorize temporal changes in MRI appearances of the prostate in patients who underwent focal therapy with MRI follow-up. METHODS: The Institutional Review Board approved this retrospective study and waived the requirement for informed consent. Thirty-seven patients (median age 61; 48-70 years) with low-to-intermediate-risk, clinically organ-confined prostate cancer underwent focal ablation therapy from 2009 to 2014. Two radiologists reviewed post-treatment MRIs (n = 76) and categorized imaging features blinded to the time interval between the focal therapy and the follow-up MRI. Inter-reader agreement was assessed (kappa) and generalized linear regression was used to examine associations between an imaging feature being present/absent and days between ablation and MRI. RESULTS: Inter-reader agreement on MRI features ranged from fair to substantial. Edema was found present at earlier times after ablation (median 16-25 days compared to MRIs without edema, median 252-514 days), as was rim enhancement of the ablation zone (18-22.5 days vs. 409-593 days), a hypointense rim around the ablation zone on T2-weighted images (53-57.5 days vs. 279-409 days) and the presence of an appreciable ablation cavity (48.5-60 days vs. 613-798 days, all p < 0.05). Enhancement of the ablation zone/scar (553-731 days vs. 61.5-162 days) and the formation of a T2-hypointense scar were found to be present on later MRI scans (514-553 days vs. 29-32 days, one reader). CONCLUSIONS: The MRI appearance of the prostate after focal ablation changes substantially over time. Identification of temporal patterns in the appearance of imaging features should help reduce image interpretation variability and errors when assessing post-therapeutic scans.
PURPOSE: The purpose of our study was to retrospectively evaluate and categorize temporal changes in MRI appearances of the prostate in patients who underwent focal therapy with MRI follow-up. METHODS: The Institutional Review Board approved this retrospective study and waived the requirement for informed consent. Thirty-seven patients (median age 61; 48-70 years) with low-to-intermediate-risk, clinically organ-confined prostate cancer underwent focal ablation therapy from 2009 to 2014. Two radiologists reviewed post-treatment MRIs (n = 76) and categorized imaging features blinded to the time interval between the focal therapy and the follow-up MRI. Inter-reader agreement was assessed (kappa) and generalized linear regression was used to examine associations between an imaging feature being present/absent and days between ablation and MRI. RESULTS: Inter-reader agreement on MRI features ranged from fair to substantial. Edema was found present at earlier times after ablation (median 16-25 days compared to MRIs without edema, median 252-514 days), as was rim enhancement of the ablation zone (18-22.5 days vs. 409-593 days), a hypointense rim around the ablation zone on T2-weighted images (53-57.5 days vs. 279-409 days) and the presence of an appreciable ablation cavity (48.5-60 days vs. 613-798 days, all p < 0.05). Enhancement of the ablation zone/scar (553-731 days vs. 61.5-162 days) and the formation of a T2-hypointense scar were found to be present on later MRI scans (514-553 days vs. 29-32 days, one reader). CONCLUSIONS: The MRI appearance of the prostate after focal ablation changes substantially over time. Identification of temporal patterns in the appearance of imaging features should help reduce image interpretation variability and errors when assessing post-therapeutic scans.
Entities:
Keywords:
Cryosurgery; Electroporation; Magnetic resonance imaging; Prostate cancer; Recurrence
Authors: Pieter J De Visschere; Gert O De Meerleer; Jurgen J Fütterer; Geert M Villeirs Journal: AJR Am J Roentgenol Date: 2010-06 Impact factor: 3.959
Authors: B G Muller; W van den Bos; M Brausi; J J Fütterer; S Ghai; P A Pinto; I V Popeneciu; T M de Reijke; C Robertson; J J M C H de la Rosette; S Scionti; B Turkbey; H Wijkstra; O Ukimura; T J Polascik Journal: World J Urol Date: 2015-01-06 Impact factor: 4.226
Authors: Oguz Akin; Christopher C Riedl; Nicole M Ishill; Chaya S Moskowitz; Jingbo Zhang; Hedvig Hricak Journal: Eur Radiol Date: 2010-04 Impact factor: 5.315
Authors: Badar M Mian; David J Lehr; Courtenay K Moore; Hugh A G Fisher; Ronald P Kaufman; Jeffery S Ross; Timothy A Jennings; Tipu Nazeer Journal: Urology Date: 2006-02 Impact factor: 2.649
Authors: Alexander P S Kirkham; Mark Emberton; Ivan M Hoh; Rowland O Illing; A Alex Freeman; Clare Allen Journal: Radiology Date: 2008-01-25 Impact factor: 11.105
Authors: Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton Journal: Lancet Date: 2017-01-20 Impact factor: 79.321
Authors: Hashim U Ahmed; Richard G Hindley; Louise Dickinson; Alex Freeman; Alex P Kirkham; Mahua Sahu; Rebecca Scott; Clare Allen; Jan Van der Meulen; Mark Emberton Journal: Lancet Oncol Date: 2012-04-17 Impact factor: 41.316
Authors: Marieke van Son; Max Peters; Marinus Moerland; Linda Kerkmeijer; Jan Lagendijk; Jochem van der Voort van Zyp Journal: Cancers (Basel) Date: 2018-12-03 Impact factor: 6.639
Authors: Mark Paxton; Eitan Barbalat; Nathan Perlis; Ravi J Menezes; Mark Gertner; David Dragas; Masoom A Haider; Antonio Finelli; John Trachtenberg; Sangeet Ghai Journal: Br J Radiol Date: 2021-07-29 Impact factor: 3.039